Photo of Hagop Kantarjian from mdanderson.org
Jan 18, 2024, 11:27
Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:
“Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia (R/R ALL). Study now amended to add navitoclax (BCL-xL inhibitor).”
Read further.
Source: Hagop Kantarjian/X
Aug 14, 2024, 18:18